ID   MGH121 Res#1
AC   CVCL_E4DN
SY   MGH121 Res # 1
RX   PubMed=25964297;
CC   Selected for resistance to: ChEBI; CHEBI_61400; WZ4002 (N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Unexplicit; Ex19del; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Cys797Ser (c.2389T>A); ClinVar=VCV000376342; Zygosity=Heterozygous; Note=Responsible for resistance to WZ4002. Located in the same allele as the p.Thr790Met mutation (PubMed=25964297).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous (PubMed=25964297).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C2926; Lung non-small cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_DH49 ! MGH121
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 19-12-24; Last updated: 19-12-24; Version: 1
//
RX   PubMed=25964297; DOI=10.1158/1078-0432.CCR-15-0560; PMCID=PMC4587765;
RA   Niederst M.J., Hu H.-C., Mulvey H.E., Lockerman E.L., Garcia A.R.,
RA   Piotrowska Z., Sequist L.V., Engelman J.A.;
RT   "The allelic context of the C797S mutation acquired upon treatment
RT   with third-generation EGFR inhibitors impacts sensitivity to
RT   subsequent treatment strategies.";
RL   Clin. Cancer Res. 21:3924-3933(2015).
//